The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population

Oncology (Switzerland)

Volumn 86, Issue 1, 2014, Pages 16-21

  Adamo, Vincenzo ^a   Ricciardi, Giuseppina Rosaria Rita ^a   Adamo, Barbara ^a   Ferraro, Giuseppa ^a   Franchina, Tindara ^a   Rossello, Rosalba ^a   Zanghì, Mariangela ^a   Cicero, Giuseppe ^b   Rizzo, Sergio ^b   Caristi, Nicola ^a   Russo, Antonio ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Breast cancer; Elderly patients; Human epidermal growth factor receptor type 2; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; NAVELBINE; TRASTUZUMAB; ANTHRACYCLINE; DEXAMETHASONE;

AGED; ALLERGIC REACTION; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILL; CONGESTIVE HEART FAILURE; DISEASES; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GERIATRIC ASSESSMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIDIMENSIONAL GERIATRIC ASSESSMENT; MULTIPLE CYCLE TREATMENT; OBESITY; PATIENT MONITORING; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; TACHYCARDIA; VERY ELDERLY; BORDERLINE HYPERTENSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HEART EJECTION FRACTION; HEART FUNCTION; HORMONAL THERAPY; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT HISTORY OF RADIOTHERAPY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; THROMBOPHLEBITIS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84893055153     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000353450     Document Type: Article

References (36)

1. American Cancer Society: Cancer Facts and Figures 2006. Atlanta, American Society, 2006. http://www.cancer.org .
2. National Cancer Institute, Bethesda: Surveillance, Epidemiology, and End Results (SEER): Cancer Statistic Review 1975-2001. http:// seer.cancer.gov/csr/ 1975-2001 .
3. Héry C, Ferlay J, Boniol M, Autier P: Changes in breast cancer incidence and mortality in middle-Aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008; 19: 1009-1018
4. Surveillance, Epidemiology and End Results (SEER) Program. Public use CD-ROM (1973-1995), Bethesda. Cancer Statistics Branch, National Cancer Institute, 1998
5. Zappa M, Visioli CB, Ciatto S: Mammography screening in elderly women: Efficacy and cost effectiveness. Crit Rev Oncol Hematol 2003; 46: 235-239
6. Jatoi I, Chen BE, Anderson WF, Rosemberg PS: Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007; 25: 1683-1690
7. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003; 21: 3580-3587
8. Spano JP, Falandry C, Chaibi P, Freyer G: Current targeted therapies in breast cancer: Clinical applications in the elderly woman. Oncologist 2011; 16: 1144-1153
9. Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret JM, Piccart M, Larsimont D: A significant proportion of elderly patients develop hormone-dependent 'luminal-B' tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008; 67: 80-92
10. Valabrega G, Montemurro F, Aglietta M: Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672
13. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
15. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274
16. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820
17. Slamon DJ, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Abstract (A-52) 29th Annual San Antonio Breast Cancer Symposium, San Antonio, 14-17 December 2006
18. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds): SEER Cancer Statistics Review, 1975-2003. Bethesda, National Cancer Institute, 2006. http://seer.cancer.gov/ csr/1975-2003/, based on November 2005 SEER data submission
19. Dellapasqua S, Colleoni M, Castiglione M, Goldhirsch A: New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. Oncologist 2007; 12: 952-959
20. Balducci L, Yates J: General guidelines for the management of older patients with cancer. Oncology 2000; 14(11A):221-227
21. Giordano SH, Hortobaygi GN, Kau SW, Theriault RL, Bondy ML: Breast cancer treatment guidelines in older women. J Clin Oncol 2005; 23: 783-791
22. Adamo V, Franchina T, Adamo B, Ferraro G, Rossello R, Maugeri Saccà M, Scibilia C, Valerio MR, Russo A: Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: GOIM study long-Term clinical experience. Ann Oncol 2007; 18(suppl 6):vi1-vi5
23. Yavas O, Yazici M, Eren O, Oyan B: The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly 2007; 137: 556-558
24. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51
25. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC: Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23: 7685-7696
26. National Library for Health-News and RSS Article: Long-Term herceptin use poses 'acceptable' cardiac risk. https://www.library. nhs.uk/rss/newsAn- dRssArticle.aspx .
27. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ: Long-Term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-4115
28. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV: Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: A meta-Analysis of published randomized trials. BMC Cancer 2007;7:153
29. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ: Trastuzumab-Associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-3865
30. Sawaki M, Mukai H, Tokudome N, Nakayama T, Taira N, Mizuno T, Yamamoto Y, Horio A, Watanabe T, Uemura Y, Ohashi Y: Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: A multicenter cohort study. Breast Cancer 2012; 19: 253-258
31. Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y: Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 2011; 41: 709-712
32. Ring A: The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer. Crit Rev Oncol Hematol 2010; 76: 127-132
33. Serrano C, Cortés J, De Mattos-Arruda L, et al: Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors. Ann Oncol 2012; 23: 897-902
34. Brollo J, Curigliano G, Disalvatore D, et al: Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treat Rev 2013; 39: 44-50
35. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-2756
36. Vicente C, Serrano N, Agustín MJ, Alonso V, Palomo P, Huarte R: Cardiotoxicity associated with trastuzumab in normal clinical practice. Farm Hosp 2009; 33: 202-207